Christopher Scott Stauffer

Christopher Scott Stauffer

Auto-generated profile, based on publicly available information

Christopher Scott Stauffer

Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; Department of Mental Health, VA Portland Health Care System, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2019 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
ATAlexander Trope
Alexander Trope
BABrian Anderson
Brian Anderson
AHAndrew R. Hooker
Andrew R. Hooker
GGGiancarlo Glick
Giancarlo Glick
CSChristopher Stauffer
Christopher Stauffer
JWJoshua D. Woolley
Joshua D. Woolley
Contemporary research with classic psychedelic drugs (e.g., lysergic acid diethylamide (LSD) and psilocybin) is indebted to the twentieth-century researchers and clinicians who generated valuable clinical knowledge of these substances through experimentation. Several recent reviews that highlight the contributions of this early literature have focused on psychedelic-assisted individual psychotherapy modalities. None have attempted to systematically identify and compile experimental studies of psychedelic-assisted group therapy. In therapeutic settings, psychedelics were often used to enhance group therapy for a variety of populations and clinical indications. We report on the results of a systematic review of the published literature in English and Spanish on psychedelic-assisted group therapies. Publications are characterized by their clinical approach, experimental method, and clinical outcomes. Given the renewed interest in the clinical use of psychedelic medicines, this review aims to stimulate hypotheses to be tested in future research on psychedelic-assisted psychotherapy, group process, and interpersonal functioning.

7 March 2022 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
ASAryan Sarparast
Aryan Sarparast
KTKelan Thomas
Kelan Thomas
BMBenjamin Malcolm
Benjamin Malcolm
CSChristopher S. Stauffer
Christopher S. Stauffer

1 December 2019 in Addictive Behaviors Reports
Verified
Journal Article
Open access
RRRachel Rapier
Rachel Rapier
SMScott McKernan
Scott McKernan
CSChristopher S. Stauffer
Christopher S. Stauffer
Social isolation and alcohol and substance use disorders (ASUD) have been identified as global health risks. Social support is protective against developing ASUD and is associated with beneficial addiction treatment outcomes. Socially stigmatized populations are at higher risk of both social isolation and ASUD, and the link between social support and substance use in these populations has been less researched than in general substance-using populations. We hypothesized that perceived social support, as measured by the Social Provisions Scale (SPS), would have an inverse relationship with frequency of substance use, from subsections of the Addiction Severity Index (ASI) that estimate use over the past 30 days and over an individual's lifetime. Using a cross-sectional design, we conducted secondary correlational analyses with pre-existing data to test our hypothesis in two separate samples made up of socially marginalized populations entering ASUD treatment programs. Sample 1: substance-using male prison inmates (n = 72, average age = 30.79) and Sample 2: primary methamphetamine-using men who have sex with men (n = 86, average age = 43.41). Significant negative correlations were found between SPS and lifetime use of alcohol, tobacco, and cannabis (r s - 0.27, -0.39, -0.26; p-values 0.04, 0.001, 0.04, respectively) in Sample 1 and 30-day use of methamphetamine (r s - 0.28; p-value 0.008) in Sample 2. Differences in results between the samples (lifetime vs 30-day use) may reflect psychosocial and contextual differences impacting perceived social support. Our findings provide support for an important link between perceived social support and frequency of substance use in socially stigmatized populations.

9 December 2020 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
CSChristopher S Stauffer
Christopher S Stauffer
BABrian T Anderson
Brian T Anderson
KOKile M. Ortigo
Kile M. Ortigo
JWJoshua Woolley
Joshua Woolley

29 March 2016 in Addiction Research & Theory
Verified
Journal Article
Closed access
PDF file
CSChristopher S. Stauffer
Christopher S. Stauffer
VMVivek Musinipally
Vivek Musinipally
ASAngela Suen
Angela Suen
KLKara L. Lynch
Kara L. Lynch
BSBrad Shapiro
Brad Shapiro
JWJoshua D. Woolley
Joshua D. Woolley
About 30–60% of the patients receiving methadone for opioid use disorder (OUD) actively use cocaine. Cocaine use disorder (CUD) has no FDA-approved pharmacological treatment; existing psychosocial treatments are inadequate. Oxytocin (OT), a social neuropeptide, has preclinical promise as an adjunctive treatment for both OUD and CUD. Twenty-two individuals receiving methadone for OUD with co-occurring CUD were randomized to receive OT or placebo intranasally 40 IU twice daily for two weeks. A priori aims were feasibility and safety. Exploratory effectiveness aims included laboratory-based measures of drug craving, drug-related implicit cognition, and drug use. High retention rates (93.5%), the absence of study-related adverse events, and the fact that OT was well tolerated in this population support the feasibility of larger trials. Two weeks of OT (but not placebo) significantly reduced cocaine craving at day 15 compared to baseline (mean change ± SD: OT = −0.23 ± 0.19, p = 0.004; PL = −0.16 ± 0.29, p = 0.114). For heroin craving, the placebo group reported a trend-level increase over time while the OT group remained unchanged – with medium to large effect sizes between the groups (Cohen’s d = 0.71–0.90). OT led to a significant switch from implicit self-association with drugs to implicitly associating drugs with others (mean change ± SD: 0.25 ± 0.35, p = 0.037) and a trend-level reduction in self-reported cocaine use over time (Z = −1.78, p = 0.075). Furthermore, OT significantly increased the accuracy of self-reported cocaine use when correlated with quantitative urine levels of cocaine metabolite. This proof-of-concept study provides promising early evidence that OT may be an effective adjunct to the treatment of co-occurring CUD and OUD. Further investigation with larger trials is warranted.

10 October 2022 in Frontiers in Psychiatry
Verified
Journal Article
Open access
CSChristopher S. Stauffer
Christopher S. Stauffer
MBMelanie R. Brown
Melanie R. Brown
DADee Adams
Dee Adams
MCMarca Cassity
Marca Cassity
JSJae Sevelius
Jae Sevelius
Introduction: Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the treatment of PTSD. Issues related to equitable access, power imbalances in the therapeutic relationship, and vulnerable states of consciousness occasioned by MDMA are magnified when working with people affected by structural vulnerabilities and health disparities, and community engagement in research planning and implementation is essential. To inform the inclusion and safety of TGD people in future MDMA-assisted psychotherapy research, the aims of the current study were to: characterize TGD experiences with trauma-related mental health care, assess openness of TGD people to participate in experimental PTSD research, and to gather specific feedback on protocol design for conducting MDMA-assisted psychotherapy with TGD people.Materials and methods: We conducted three virtual focus group discussions (FGDs) with 5–6 participants each (N = 17). Eligible TGD participants had a history of receiving trauma-related mental health care. Each FGD was facilitated by two licensed clinicians who identified as TGD. Qualitative data analysis was conducted via an iterative process of identification of recurrent patterns and themes.Results: We have identified several key issues TGD people face when seeking and engaging in trauma-related mental health care, including barriers to receiving adequate gender-affirming and trauma-informed mental health care and frustration with providers lacking cultural humility. Suggested amendments to MDMA-assisted psychotherapy protocols include: routine collection of trans-inclusive gender identity data, implementing an explicit gender-affirming treatment approach, ensuring a culturally safe setting, and diversifying co-therapy dyads.Discussion: The inclusion of TGD voices in early conversations about emerging experimental PTSD interventions promotes equitable access, in the context of health and healthcare disparities, and helps researchers understand the needs of the community and tailor research to meet those needs. Through an ongoing conversation with the TGD community, we aim to incorporate a gender-affirming approach into existing research protocols and inform future applications of MDMA-assisted psychotherapy in addressing the effects of minority stress and boosting resilience.